GWP.L Regulatory News (GWP)

23 Mar 2005 07:00

GW Pharmaceuticals PLC23 March 2005 For Immediate Release 23 March 2005 GW Pharmaceuticals plc ("GW" or "the Company") Appointment of Dr Stephen Wright as Director GW is pleased to announce the promotion of Dr Stephen Wright to GW's Board ofDirectors with immediate effect. Dr Wright (age 53) joined GW's senior management team in January 2004 asResearch & Development Director. He will retain this title in his new capacityas a main Board director. Dr Wright joined GW from Ipsen, a major private European pharmaceutical companywith turnover in excess of €700m, where he was Senior Vice President, Clinical R&D. Previous positions include Venture Head in Neurosciences and MedicalDirector of Immunosciences at Abbott Laboratories in the US. He has also heldposts as Associate Medical Director at Glaxo Wellcome and Director ofImmunology, Inflammation and Dermatology at Scotia Pharmaceuticals. Dr Geoffrey Guy, Executive Chairman, commented: "Since joining GW's seniormanagement team last year, Stephen has made a valuable contribution to theCompany in advancing its research and development activities. He has animpressive track record in pharmaceutical R&D across large, medium and smallcompanies, with particular expertise in neuroscience development and also priorexperience in plant derived medicines. I am therefore delighted that Stephen hasjoined our Board and look forward to him playing an important role incontributing to the future success of GW." A list of Stephen Wright's current and former directorships is attached as anappendix to this announcement. - Ends - Enquiries: GW Pharmaceuticals plc 01980 557 000Dr Geoffrey Guy, Executive ChairmanJustin Gover, Managing Director Weber Shandwick Square Mile 020 7067 0700Kevin Smith Appendix STEPHEN WRIGHT - LIST OF CURRENT AND FORMER DIRECTORSHIPS & PARTNERSHIPS Former directorships or partnerships held since 1 March 2000: Ipsen Limited Current directorships: S & K Pharma Consulting Limited There are no further disclosures to be made in respect of Stephen Wrightpursuant to paragraph (f) of Schedule 2 of the AiM Rules for companies. This information is provided by RNS The company news service from the London Stock Exchange